Lack of association between insulin-like growth factor-1 or insulin-like growth factor-binding protein-3 and left ventricular hypertrophy: Results of the Study of Health in Pomerania

Journal of Hypertension

Volumn 28, Issue 4, 2010, Pages 856-864

  Friedrich, Nele ^a   Aumann, Nicole ^a   Dörr, Marcus ^a   Felix, Stephan B ^a   Nauck, Matthias ^a   Wallaschofski, Henri ^a   Völzke, Henry ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Insulin like growth factor 1; Insulin like growth factor binding protein 3; Left ventricular hypertrophy; Study of health in pomerania

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 78650777015     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328336274a     Document Type: Article

References (70)

1. Galderisi M, Vitale G, Lupoli G, Barbieri M, Varricchio G, Carella C, et al. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension 2001; 38:840-845.
2. Sundstrom J, Lind L, Nystrom N, Zethelius B, Andren B, Hales CN, et al. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation 2000; 101:2595-2600.
3. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31:1635-1640.
4. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality: results from the Framingham study. Cardiology 1992; 81:291-298.
5. Antoniucci D, Seccareccia F, Menotti A, Dovellini EV, Prati PL, Rovelli F, et al. Prevalence and correlates of echocardiographic determined left ventricular hypertrophy in 2318 asymptomatic middle-aged men: the ECCIS project. Epidemiolgia e Clinica della Cardiopatia Ischemica Silente. G Ital Cardiol 1997; 27:363-369.
6. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart study). Am J Cardiol 1991; 68:85-89.
7. Kuch B, Schunkert H, Muscholl M, Doring A, von Scheidt W, Hense HW. Distribution, determinants and reference values of left ventricular parameters in the general population: results of the MONICA/KORA echocardiography studies. Gesundheitswesen 2005; 67 (Suppl 1):S68-S73.
8. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990; 70:591-614.
9. Rinderknecht E, Humbel RE. The amino acid sequence of human insulinlike growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253:2769-2776.
10. Mathews LS, Norstedt G, Palmiter RD. Regulation of insulin-like growth factor I gene expression by growth hormone. Proc Natl Acad Sci U S A 1986; 83:9343-9347.
11. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997; 29:691-699.
12. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102-152.
13. Colao A, di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001; 86:1874-1881.
14. Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, di Somma C, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002; 87:3097-3104.
15. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100:1802-1807.
16. Diez J, Laviades C, Martinez E, Gil MJ, Monreal I, Fernandez J, et al. Insulinlike growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy. J Hypertens 1995; 13:349-355.
17. Laviades C, Mayor G, Diez J. Elevated circulating levels of insulin-like growth factor I in essential hypertensive patients with left ventricular hypertrophy. Arch Mal Coeur Vaiss 1991; 84:1039-1041.
18. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87:1715-1721.
19. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, et al. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994; 89:799-809.
20. Ren J, Jefferson L, Sowers JR, Brown RA. Influence of age on contractile response to insulin-like growth factor 1 in ventricular myocytes from spontaneously hypertensive rats. Hypertension 1999; 34:1215-1222. (Pubitemid 30002385)
21. Rabkin SW, Dawson KG, Bhaumick B, O'Brein E, Kendler DL. Serum insulin, IGF-I, IGF-II and growth hormone, and left ventricular mass in noninsulin-dependent mellitus. Can J Cardiol 1996; 12:264-270.
22. Sesti G, Sciacqua A, Scozzafava A, Vatrano M, Angotti E, Ruberto C, et al. Effects of growth hormone and insulin-like growth factor-1 on cardiac hypertrophy of hypertensive patients. J Hypertens 2007; 25:471-477.
23. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16:3-34.
24. John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, et al. Study of Health in Pomerania (SHIP): a health examination survey in an east German region - objectives and design. Soz Praventivmed 2001; 46:186-194.
25. Keil U, Stieber J, Doring A, Chambless L, Hartel U, Filipiak B, et al. The cardiovascular risk factor profile in the study area Augsburg. Results from the first MONICA survey 1984/85. Acta Med Scand Suppl 1988; 728:119-128.
26. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
27. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
28. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 1999; 50:703-713.
29. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108.
30. Markus MR, Stritzke J, Lieb W, Mayer B, Luchner A, Doring A, et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. J Hypertens 2008; 26:2040-2049.
31. Friedrich N, Alte D, Volzke H, Spilcke-Liss E, Ludemann J, Lerch MM, et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res 2008; 18:228-237.
32. Span JP, Pieters GF, Sweep FG, Hermus AR, Smals AG. Gender differences in rhGH-induced changes in body composition in GH-deficient adults. J Clin Endocrinol Metab 2001; 86:4161-4165.
33. Unden AL, Elofsson S, Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clin Endocrinol (Oxf) 2005; 63:94-102.
34. Kuch B, Muscholl M, Luchner A, Doring A, Riegger GA, Schunkert H, et al. Gender specific differences in left ventricular adaptation to obesity and hypertension. J Hum Hypertens 1998; 12:685-691.
35. Friedrich N, Rosskopf D, Brabant G, Volzke H, Nauck M, Wallaschofski H. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the study of Health in Pomerania (SHIP). Exp Clin Endocrinol Diabetes 2009. [Epub ahead of print].
36. Hietaniemi M, Poykko SM, Ukkola O, Paivansalo M, Antero Kesaniemi Y. IGF-I concentrations are positively associated with carotid artery atherosclerosis in women. Ann Med 2005; 37:373-382.
37. Engstrom BE, Karlsson FA, Wide L. Marked gender differences in ambulatory morning growth hormone values in young adults. Clin Chem 1998; 44:1289-1295.
38. Vahl N, Moller N, Lauritzen T, Christiansen JS, Jorgensen JO. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J Clin Endocrinol Metab 1997; 82:3612-3618. (Pubitemid 27509345)
39. Pucci A, Zanini C, Granata R, Ghignone R, Iavarone A, Broglio F, et al. Myocardial insulin-like growth factor-1 and insulin-like growth factor binding protein-3 gene expression in failing hearts harvested from patients undergoing cardiac transplantation. J Heart Lung Transplant 2009; 28:402-405.
40. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-1558.
41. Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlof B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr 2008; 9:809-815.
42. Patel DA, Srinivasan SR, Chen W, Berenson GS. Influence of the metabolic syndrome versus the sum of its individual components on left ventricular geometry in young adults (from the Bogalusa Heart study). Am J Cardiol 2009; 104:69-73.
43. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, et al. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 2008; 118:2252-2258; 5p following 2258.
44. Zabalgoitia M, Berning J, Koren MJ, Stoylen A, Nieminen MS, Dahlof B, et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). Am J Cardiol 2001; 88:646-650. (Pubitemid 32831098)
45. de Simone G. Concentric or eccentric hypertrophy: how clinically relevant is the difference? Hypertension 2004; 43:714-715.
46. Wolff B, Volzke H, Ludemann J, Robinson D, Vogelgesang D, Staudt A, et al. Association between high serum ferritin levels and carotid atherosclerosis in the Study of Health in Pomerania (SHIP). Stroke 2004; 35:453-457.
47. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25:871-878.
48. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994; 45:598-604.
49. Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR. Insulinlike growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996; 137:1798-1803.
50. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res 2008; 79:238-248.
51. Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, Fu M, et al. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol 2006; 291:H787-796.
52. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart study. Circulation 2003; 107:448-454.
53. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with noninsulin-dependent diabetes mellitus. Circulation 2001; 103:1238-1244.
54. Meisinger C, Heier M, Volzke H, Lowel H, Mitusch R, Hense HW, et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24:293-299.
55. Volzke H, Stritzke J, Kuch B, Schmidt CO, Ludemann J, Doring A, et al. Regional differences in the prevalence of left ventricular hypertrophy within Germany. Eur J Cardiovasc Prev Rehabil 2009.
56. Cuspidi C, Lonati L, Macca G, Sampieri L, Fusi V, Michev I, et al. Prevalence of left ventricular hypertrophy and carotid thickening in a large selected hypertensive population: impact of different echocardiographic and ultrasonographic diagnostic criteria. Blood Press 2001; 10:142-149.
57. Vasan RS, Glazer NL, Felix JF, Lieb W, Wild PS, Felix SB, et al. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA 2009; 302:168-178.
58. Haring R, Volzke H, Felix SB, Schipf S, Dorr M., Rosskopf D, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the Study of Health in Pomerania. Diabetes 2009; 58:2027-2031.
59. Volzke H, Nauck M, Rettig R, Dorr M, Higham C, Brabant G, et al. Association between hepatic steatosis and serum IGF1 and IGFBP3 levels in a population-based sample. Eur J Endocrinol 2009; 161:705-713.
60. Friedrich N, Volzke H, Hampe J, Lerch MM, Jorgensen T. Known risk factors do not explain disparities in gallstone prevalence between Denmark and northeast Germany. Am J Gastroenterol 2009; 104:89-95.
61. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart study. Ann Intern Med 2003; 139:642-648.
62. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 2003; 107:346-354. (Pubitemid 36135235)
63. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo study. Am J Epidemiol 1997; 145:970-976.
64. Harris TB, Kiel D, Roubenoff R, Langlois J, Hannan M, Havlik R, et al. Association of insulin-like growth factor-I with body composition, weight history, and past health behaviors in the very old: the Framingham Heart study. J Am Geriatr Soc 1997; 45:133-139.
65. Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB. Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 1993; 22:1873-1880.
66. Copeland KC, Colletti RB, Devlin JT, McAuliffe TL. The relationship between insulin-like growth factor-I, adiposity, and aging. Metabolism 1990; 39:584-587.
67. de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002; 20:323-331.
68. Karasek E, Witkowska M. Neurohumoral factors in hypertensive patients with and without left ventricular hypertrophy. Pol Arch Med Wewn 2000; 103:23-33.
69. Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population: the Tromso study. Eur Heart J 1999; 20:429-438.
70. Brabant G, Wallaschofski H. Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary 2007; 10:129-133.